Formulations Dexpanthenol MDV* 250mg/ml

Dexpanthenol MDV* 250mg/ml

Available from our 503A patient specific pharmacy.
Click here to download the product insert.

Classification Injection
Sub-classification Solution
Strength (Concentration) common dose* 250mg/ml
Size (Volume) 30ml

Order today from our FDA-Registered Outsourcing Facility

Order your prescriptions now.

Order Now

*For professional use only. ImprimisRx® Pharmacy specializes in customizing medications to meet unique patient and practitioner needs. ImprimisRx® dispenses only to individually identified patients with valid prescriptions. No compounded medication is reviewed by the FDA for safety or efficacy. ImprimisRx® does not compound copies of commercially available products. References available upon request.

Potential Ingredient Risks

Possible Indications: Is a sterile, nonpyrogenic, aqueous solution indicated for prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus. Intestinal atony causing abdominal distention; postoperative or postpartum retention of flatus, or postoperative delay in resumption of intestinal motility; paralytic ileus.

Possible Adverse Effects: There have been a few reports of allergic reactions and single reports of several other adverse events in association with the administration of Dexpanthenol. A causal relationship is uncertain. One patient experienced itching, tingling, di_culty in breathing. Another patient had red patches of skin. Two patients had generalized dermatitis and one patient urticaria. One patient experienced temporary respiratory di_culty following administration of Dexpanthenol injection 5 minutes after succinylcholine was discontinued. One patient experienced a noticeable but slight drop in blood pressure after administration of Dexpanthenol while in the recovery room. One patient experienced intestinal colic one-half hour after the drug was administered. Two patients vomited following administration and two patients had diarrhea 10 days post-surgery and after Dexpanthenol Injection. One elderly patient became agitated after administration of the drug.

Potential Contraindications/Precautions: If any signs of a hypersensitivity reaction appear, Dexpanthenol Injection should be discontinued. If ileus is a secondary consequence of mechanical obstruction, primary attention should be directed to the obstruction. The management of adynamic ileus includes the correction of any fluid and electrolyte imbalance (especially hypokalemia), anemia and hypoproteinemia, treatment of infection, avoidance where possible of drugs which are known to decrease gastrointestinal motility and decompression of the gastrointestinal tract when considerably distended by nasogastric suction or use of a long intestinal tube.

Storage: Store at Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).

Auxiliary Labeling: There have been rare instances of allergic reactions of unknown cause during the concomitant use of Dexpanthenol Injection with drugs such as antibiotics, narcotics and barbiturates. Dexpanthenol Injection should not be administered within one hour of succinylcholine.